Alembic Pharmaceuticals Limited (BOM: 533573)

Alembic Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Operating Revenue	63,573	62,286	56,526	53,058	53,931	46,058
Revenue	63,573	62,286	56,526	53,058	53,931	46,058
Revenue Growth (YoY)	6.02%	10.19%	6.54%	-1.62%	17.10%	17.06%
Cost of Revenue	17,444	17,962	17,748	14,982	13,402	10,904
Gross Profit	46,128	44,324	38,778	38,076	40,529	35,153
Selling, General & Admin	15,224	14,463	11,691	11,330	10,512	9,090
Other Operating Expenses	20,850	20,499	19,892	17,951	15,213	13,378
Operating Expenses	38,887	37,717	34,401	32,201	27,561	24,039
Operating Income	7,241	6,607	4,378	5,875	12,968	11,114
Interest Expense	-581	-561.9	-501.7	-177.3	-160.2	-271.6
Interest & Investment Income	20.9	20.9	3.3	17.3	15.8	17.4
Earnings From Equity Investments	7.4	-9.8	-309.2	52.8	317.4	0.5
Currency Exchange Gain (Loss)	176.9	176.9	-0.9	443.1	772.8	84.6
Other Non Operating Income (Expenses)	-25.8	4	2.4	0.5	1.7	-0.1
EBT Excluding Unusual Items	6,839	6,238	3,572	6,211	13,916	10,945
Impairment of Goodwill	-	-	-	-	-	-51.2
Gain (Loss) on Sale of Investments	43.9	43.9	7.5	28.7	62.8	9.2
Gain (Loss) on Sale of Assets	17	17	-47	5.4	13.9	11.6
Asset Writedown	-	-	-	-	-	-490.2
Other Unusual Items	128.7	-	-	-	-	-436.5
Pretax Income	7,049	6,318	3,546	6,254	13,998	9,999
Income Tax Expense	585.2	160	126.1	1,045	2,533	1,992
Earnings From Continuing Operations	6,464	6,158	3,420	5,209	11,465	8,007
Minority Interest in Earnings	4.3	-	-	-	-	281.2
Net Income	6,468	6,158	3,420	5,209	11,465	8,288
Net Income to Common	6,468	6,158	3,420	5,209	11,465	8,288
Net Income Growth	21.65%	80.07%	-34.35%	-54.56%	38.33%	41.83%
Shares Outstanding (Basic)	197	197	197	197	194	189
Shares Outstanding (Diluted)	197	197	197	197	194	189
Shares Change (YoY)	0.08%	-	-	1.46%	2.77%	-
EPS (Basic)	32.89	31.33	17.40	26.50	59.18	43.97
EPS (Diluted)	32.89	31.33	17.40	26.50	59.18	43.97
EPS Growth	21.56%	80.07%	-34.35%	-55.21%	34.60%	41.83%
Free Cash Flow	811.1	4,757	2,805	1,267	8,039	-2,858
Free Cash Flow Per Share	4.12	24.20	14.27	6.45	41.49	-15.16
Dividend Per Share	-	11.000	8.000	10.000	14.000	7.000
Dividend Growth	-	37.50%	-20.00%	-28.57%	100.00%	27.27%
Gross Margin	72.56%	71.16%	68.60%	71.76%	75.15%	76.32%
Operating Margin	11.39%	10.61%	7.74%	11.07%	24.05%	24.13%
Profit Margin	10.17%	9.89%	6.05%	9.82%	21.26%	18.00%
Free Cash Flow Margin	1.28%	7.64%	4.96%	2.39%	14.91%	-6.20%
EBITDA	9,832	9,141	6,962	8,585	14,663	12,549
EBITDA Margin	15.47%	14.68%	12.32%	16.18%	27.19%	27.25%
D&A For EBITDA	2,592	2,533	2,584	2,710	1,695	1,435
EBIT	7,241	6,607	4,378	5,875	12,968	11,114
EBIT Margin	11.39%	10.61%	7.74%	11.07%	24.05%	24.13%
Effective Tax Rate	8.30%	2.53%	3.56%	16.70%	18.10%	19.92%
Revenue as Reported	63,826	62,569	56,554	53,563	54,804	46,107

Source: S&P Capital IQ. Standard template. Financial Sources.